{"id":745315,"date":"2016-10-21T05:45:00","date_gmt":"2016-10-21T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/"},"modified":"2025-11-07T01:25:35","modified_gmt":"2025-11-07T06:25:35","slug":"mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/","title":{"rendered":"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival        Compared With Chemotherapy in Urothelial Cancer     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the phase 3 KEYNOTE-045 trial investigating the use<br \/>\n      of KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      therapy, in patients with previously treated advanced urothelial cancer,<br \/>\n      met the primary endpoint of overall survival (OS). In this trial,<br \/>\n      KEYTRUDA was superior compared to investigator choice chemotherapy.<br \/>\n      Based on a pre-specified interim analysis, an independent Data<br \/>\n      Monitoring Committee (DMC) has recommended that the trial be stopped<br \/>\n      early.\n    <\/p>\n<p>\n      \u201cThe results of KEYNOTE-045 represent a major breakthrough and will be<br \/>\n      welcome news for patients dealing with previously treated advanced<br \/>\n      urothelial cancer,\u201d said Dr. Roger M. Perlmutter, president, Merck<br \/>\n      Research Laboratories. \u201cWe look forward to sharing the findings from<br \/>\n      this study with the medical community and with regulatory authorities<br \/>\n      around the world.\u201d\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA in this trial was consistent with that<br \/>\n      observed in previously reported studies involving patients with advanced<br \/>\n      urothelial cancer. Results from KEYNOTE-045 will be presented at an<br \/>\n      upcoming medical meeting.\n    <\/p>\n<p>\n      The KEYTRUDA clinical development program includes more than 30 tumor<br \/>\n      types in more than 360 clinical trials, including nearly 200 trials that<br \/>\n      combine KEYTRUDA with other cancer treatments. For genitourinary<br \/>\n      cancers, Merck has the largest immuno-oncology clinical development<br \/>\n      program in bladder cancer, with 27 trials underway involving KEYTRUDA as<br \/>\n      monotherapy and in combination, including four registration-enabling<br \/>\n      studies.\n    <\/p>\n<p>\n      <b>About KEYNOTE-045<\/b>\n    <\/p>\n<p>\n      KEYNOTE-045 is a randomized, pivotal, phase 3 study (ClinicalTrials.gov,<br \/>\n      NCT02256436) evaluating KEYTRUDA monotherapy compared to<br \/>\n      investigator-choice chemotherapy (paclitaxel, docetaxel, vinflunine) in<br \/>\n      the treatment of patients with metastatic or locally advanced or<br \/>\n      unresectable (inoperable) urothelial cancer that has recurred or<br \/>\n      progressed following platinum-based chemotherapy. The co-primary<br \/>\n      endpoints are overall survival (OS) and progression-free survival (PFS);<br \/>\n      secondary endpoints are overall response rate (ORR), duration of<br \/>\n      response (DOR), and safety. The study randomized 542 patients to receive<br \/>\n      KEYTRUDA (200 mg every three weeks) or investigator-choice of paclitaxel<br \/>\n      (175 mg\/m<sup>2<\/sup> every three weeks), docetaxel (75 mg\/m<sup>2<\/sup><br \/>\n      every three weeks), or vinflunine (320 mg\/m<sup>2 <\/sup>every three<br \/>\n      weeks).\n    <\/p>\n<p>\n      <b>About Bladder Cancer<\/b>\n    <\/p>\n<p>\n      Bladder cancer begins when cells in the urinary bladder start to grow<br \/>\n      uncontrollably. As more cancer cells develop, they can form a tumor and<br \/>\n      spread to other areas of the body. Urothelial carcinoma, the most common<br \/>\n      type of bladder cancer, starts in the urothelial cells that line the<br \/>\n      inside of the bladder. In 2012, approximately 430,000 people worldwide<br \/>\n      were diagnosed with bladder cancer and 165,000 died from the disease.<br \/>\n      The incidence of bladder cancer is elevated in North America, Europe,<br \/>\n      North Africa, the Middle East, Australia and New Zealand.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy, at a dose of 2 mg\/kg every three<br \/>\n      weeks. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n      disease progression on FDA-approved therapy for these aberrations prior<br \/>\n      to receiving KEYTRUDA. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response. An<br \/>\n      improvement in survival or disease-related symptoms has not yet been<br \/>\n      established. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy at a fixed dose<br \/>\n      of 200 mg every three weeks. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2.0%) of 1567 patients<br \/>\n      with melanoma, including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%)<br \/>\n      pneumonitis. Pneumonitis occurred in 19 (3.5%) of 550 patients with<br \/>\n      NSCLC, including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%)<br \/>\n      pneumonitis and more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1567 patients with<br \/>\n      melanoma, including Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis.<br \/>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Hepatitis occurred in 16 (1%) of 1567 patients with melanoma, including<br \/>\n      Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor patients for<br \/>\n      changes in liver function. Administer corticosteroids for Grade 2 or<br \/>\n      greater hepatitis and, based on severity of liver enzyme elevations,<br \/>\n      withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis.<br \/>\n      Hypophysitis occurred in 1 (0.2 %) of 550 patients with NSCLC, which was<br \/>\n      Grade 3 in severity. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism<br \/>\n      occurred in 127 (8.1%) of 1567 patients with melanoma, including Grade 3<br \/>\n      (0.1%) hypothyroidism. Hyperthyroidism occurred in 10 (1.8%) of 550<br \/>\n      patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%)<br \/>\n      hyperthyroidism. Hypothyroidism occurred in 38 (6.9%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism. New or<br \/>\n      worsening hypothyroidism occurred in 28 (14.6%) of 192 patients with<br \/>\n      HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroid disorders can<br \/>\n      occur at any time during treatment. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Nephritis occurred in 7 (0.4%) of 1567 patients with melanoma including,<br \/>\n      Grade 2 (0.2%), 3 (0.2%), and 4 (0.1%) nephritis. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients<br \/>\n      with melanoma: arthritis (1.6%), exfoliative dermatitis, bullous<br \/>\n      pemphigoid, uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. The<br \/>\n      following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients with NSCLC: rash, vasculitis,<br \/>\n      hemolytic anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients with NSCLC. Serious adverse reactions occurred in 38% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pleural effusion, pneumonia, dyspnea,<br \/>\n      pulmonary embolism, and pneumonitis. The most common adverse reactions<br \/>\n      (reported in at least 20% of patients) were fatigue (44%), cough (29%),<br \/>\n      decreased appetite (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue<br \/>\n      (46%), decreased appetite (22%), and dyspnea (20%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 360 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=6eb4cf570649fc8608f6e5b883542daf\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=b1c937c3457320f877c818e863a68d1b\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=e62f571113cf4bd489b236796e6c4854\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=687096a0ef857632093a12f19d636eeb\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=f99ba75728160e8b7c198ee3e51bedb1\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=f3cf28109c7e4ba3a28e6f642f0f7a98\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=81c5e0d4ea9c30437cd1ad125b05564f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=34f0cc90ebe3bc87f96c09cb26297755\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51443945&amp;newsitemid=20161021005182&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=bd0fa620d0ec830c19f80052b448be15\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161021005182r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. \u201cThe results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe look forward to sharing the findings from this study with the medical community and with regulatory authorities around the world.\u201d The safety profile of KEYTRUDA in this trial was consistent with that observed in previously<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745315","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. \u201cThe results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe look forward to sharing the findings from this study with the medical community and with regulatory authorities around the world.\u201d The safety profile of KEYTRUDA in this trial was consistent with that observed in previously\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\\\/\",\"name\":\"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-21T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:25:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. \u201cThe results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe look forward to sharing the findings from this study with the medical community and with regulatory authorities around the world.\u201d The safety profile of KEYTRUDA in this trial was consistent with that observed in previously","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:35+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/","name":"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-21T05:45:00+00:00","dateModified":"2025-11-07T06:25:35+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keynote-045-studying-keytruda-pembrolizumab-in-advanced-bladder-cancer-urothelial-cancer-meets-primary-endpoint-and-stops-early\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYNOTE-045 Studying KEYTRUDA\u00ae (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3719b8b2-c949-4206-b280-442dce526342","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYNOTE-045-Studying-KEYTRUDA-pembrolizumab-in-Advanced-Bladder-Cancer-Urothelial-Cancer-Meets-Primary-Endpoint-and-Stops-Early-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745315\/revisions"}],"predecessor-version":[{"id":3674722,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745315\/revisions\/3674722"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745315"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}